Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ireland screens newborns for cystic fibrosis

This article was originally published in Clinica

Executive Summary

Ireland has begun to test all newborns for cystic fibrosis (CF). From 1 July, the test for CF is being performed under its newborn bloodspot screening programme, as part of the so-called heel prick test. Until now, this tested for the following inherited conditions: phenylketonuria (PKU), maple syrup urine disease, homocystinuria, classical galactosaemia and congenital hypothyroidism. Ireland has a high incidence of CF compared with other EU countries, according to the Health Service Executive. “Early identification and care is of great benefit to children with CF,” it said.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel